Investing.com -- 艾沙株式会社 (Eisai Co.)股价当日上涨0.4%，此前一度下跌，投资者正在消化该公司季度业绩报告，报告显示其阿尔茨海默病药物乐伐替尼 (Leqembi)销售强劲增长。 这家日本制药公司报告称，第一季度乐伐替尼全球销售额同比增长269%，达到¥23.1亿。然而，这一令人印象深刻的增长包括来自中国的¥5.3亿一次性需求，这一点此前已在合作伙伴Biogen ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

在多伦多举行的阿尔茨海默病协会国际会议上展示的结果表明，在接受18个月初始治疗后，每周360毫克SC-AI维持剂量能够维持与每两周静脉注射相似的临床和生物标志物益处。艾沙制药股票的贝塔系数为-0.18，其股价走势通常与市场趋势相反，为投资组合提供潜在的多元化优势。 InvestingPro 订阅用户可以获取关于艾沙制药市场地位和增长前景的6项额外关键见解。

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.